The earnings call presented a mixed performance with growth in certain product lines and strategic acquisitions aimed at expansion. However, these were offset by significant challenges such as decreased AGGRASTAT revenue, increased costs, and a resulting negative EBITDA and net loss. The positive aspects of strategic growth were balanced by financial challenges.

Company Guidance -

Q2 2025

During the conference call, Medicure provided guidance on its financial performance for the year ended December 31, 2024, highlighting several key metrics. The company reported net revenue of $21.9 million, a slight increase from $21.7 million in the previous year, but experienced a net loss of approximately $1 million or $0.10 per share, compared to a net loss of $922,000 or $0.09 per share in the prior year. AGGRASTAT revenue decreased to $8.1 million from $9.7 million due to pricing pressures from generics, while ZYPITAMAG revenue through traditional insurance increased to $3 million from $2.4 million, attributed to greater utilization through insurance formularies. Marley Drug's net revenue rose to $10.8 million from $9.6 million, driven by changes in product mix and increased ZYPITAMAG sales. Despite these increases, adjusted EBITDA was negative $437,000, down from $1.9 million the previous year, due to higher costs of goods and R&D expenses totaling $3.1 million primarily for the MC-1 PNPO clinical trial. The company also highlighted strategic acquisitions of Gateway Medical and West Olympia Pharmacy, aiming to expand its Retail Pharmacy operating segment and create synergies with Marley Drug. Additionally, Medicure remains focused on developing new products, including a novel drug related to MC-1, with significant market potential.

Increased ZYPITAMAG Revenue

ZYPITAMAG sales through Marley Drug grew by 23% from $2.6 million in 2023 to $3.2 million in 2024. Revenue through insured channels also grew by 25% from $2.4 million in 2023 to $3 million in 2024.

Marley Drug Revenue Growth

Net revenue for Marley Drug grew by 12.5% from $9.6 million in 2023 to $10.8 million in 2024.

Strategic Acquisitions

Medicure acquired Gateway Medical and signed an agreement to acquire West Olympia Pharmacy, expanding its Retail Pharmacy segment and creating synergies with Marley Drug.

Legal Settlement Income

The company recorded $1.9 million in other income due to a legal settlement with its contract development and manufacturing organization.

Cash Position

As of December 31, 2024, Medicure had cash totaling approximately $7.2 million, an increase from $6.4 million as of December 31, 2023. The company remains debt-free.

Medicure (TSE:MPH) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

TSE:MPH Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Aug 13, 2025	2025 (Q2)	- / -	-0.117	―	―	―
May 21, 2025	2025 (Q1)	- / -	0.005	―	―	―
Apr 25, 2025	2024 (Q4)	- / -0.07	0.005	-1420.00% (-0.07)	―	―
Nov 25, 2024	2024 (Q3)	- / 0.07	0.008	712.50% (+0.06)	―	―
Aug 14, 2024	2024 (Q2)	- / -0.12	0.024	-587.50% (-0.14)	―	―
May 28, 2024	2024 (Q1)	- / -	0.028	―	―	―
Apr 08, 2024	2023 (Q4)	- / <0.01	0.028	-82.14% (-0.02)	―	―
Nov 21, 2023	2023 (Q3)	- / <0.01	0.109	-92.66% (-0.10)	―	―
Jul 29, 2023	2023 (Q2)	- / 0.02	-0.067	135.82% (+0.09)	―	―
May 26, 2023	2023 (Q1)	- / -	0.047	―	―	―

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

TSE:MPH Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
May 21, 2025	C$1.00	C$1.00	0.00%
Apr 25, 2025	C$0.83	C$0.83	0.00%
Nov 25, 2024	C$0.90	C$0.99	+10.00%
Aug 14, 2024	C$1.00	C$1.04	+4.00%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Medicure Inc (TSE:MPH) report earnings?

Medicure Inc (TSE:MPH) is schdueled to report earning on Aug 13, 2025, After Close (Confirmed).

What is Medicure Inc (TSE:MPH) earnings time?

Medicure Inc (TSE:MPH) earnings time is at Aug 13, 2025, After Close (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is TSE:MPH EPS forecast?

Currently, no data Available

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing